A UK startup is betting that quantum physics can unlock the next generation of industrial enzymes. Imperagen has raised £5 million ($6.7 million) in seed funding to build an enzyme engineering platform that fuses quantum mechanical simulations with artificial intelligence.

The round was led by PXN Ventures, with backing from IQ Capital and Northern Gritstone. The fresh capital will help the company scale its computational approach to designing enzymes that can replace toxic chemicals and reduce energy consumption across manufacturing, agriculture and pharmaceuticals.

A New Way to Design Enzymes

Traditional enzyme engineering relies on trial and error or directed evolution, which can be slow and expensive. Imperagen takes a different route. The company uses quantum physics models to simulate how enzymes behave at the molecular level. These simulations generate vast datasets that feed into machine learning algorithms. The AI then predicts which enzyme structures will perform best for a given task.

This combination could dramatically shorten the development timeline. Instead of screening millions of variants in a lab, the startup says its platform can identify high-performing candidates in silico within weeks.

Why This Matters

Enzymes are nature's catalysts, enabling everything from digestion to fermentation. But natural enzymes rarely fit industrial needs. Companies often need customized enzymes that can withstand high temperatures, extreme pH levels or novel chemical reactions.

Imperagen's technology could make custom enzyme design faster and more predictable. That is critical for industries looking to replace petrochemical-based processes with biological alternatives. If successful, the platform could help manufacturers reduce waste, cut carbon emissions and move toward circular production models. The funding suggests investors see a growing market for computational biology tools that address real-world sustainability challenges.

The company is headquartered in Manchester, UK, and plans to expand its team of computational scientists and engineers. It has not disclosed specific enzyme targets or partners yet, but the seed round positions it to move toward commercial applications.